COVID-19 antibody seroprevalence in Santa Clara County, California.
COVID-19 antibody seroprevalence in Santa Clara County, California.
复制标题
DOI：
10.1093/ije/dyab010
复制
发表时间：
2021-05-17
影响因子：
7.7
通讯作者：
Bhattacharya J
中科院分区：
文献类型：
--
作者：
Bendavid E;Mulaney B;Sood N;Shah S;Bromley-Dulfano R;Lai C;Weissberg Z;Saavedra-Walker R;Tedrow J;Bogan A;Kupiec T;Eichner D;Gupta R;Ioannidis JPA;Bhattacharya J
测量严重急性呼吸道综合征冠状病毒2（SARS-CoV-2）抗体的血清阳性率对于了解感染风险和死亡率至关重要。我们研究了从圣克拉拉县抽取的社区样本中的2019冠状病毒病（COVID-19）抗体血清阳性率。于2020年4月3日及4日，我们使用快速侧流检测法（Premier Biotech）检测了3328名县居民的SARS-CoV-2免疫球蛋白G（IgG）和免疫球蛋白M（IgM）抗体。参与者是通过广告招募的，这些广告的目标是接触到与县人口性别、种族/民族和居住地邮政编码相匹配的县居民。我们估计权重，以匹配我们的样本到县邮政，年龄，性别和种族/民族。我们报告了SARS-CoV-2抗体的加权和未加权患病率。我们通过结合来自18个独立的检测试剂盒评估的数据来调整检测性能特征：14个用于特异性，4个用于敏感性。我们样本中抗体的原始患病率为1.5% [精确二项式95%置信区间（CI）1.1-2.0%]。在我们的数据中，测试性能特异性为99.5%（95%CI 99.2-99.7%），灵敏度为82.8%（95%CI 76.0-88.4%）。经测试性能特征调整的未加权患病率为1.2%（95% CI 0.7-1.8%）。人口统计学加权后，患病率为2.8%（95% CI 1.3-4.2%），使用bootstrap估计置信区间。这些患病率点估计值意味着，截至3月下旬，圣克拉拉县有53 000人[使用加权患病率的95% CI 26 000 - 82 000;使用未加权患病率的23 000人（95% CI 14 000-35 000）]被感染，远远超过当时的1200例确诊病例。圣克拉拉县SARS-CoV-2抗体的估计流行率表明，COVID-19的传播范围可能比2020年3月下旬的病例数更广。当时，圣克拉拉县等低负担地区远未达到免疫阈值。
Measuring the seroprevalence of antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is central to understanding infection risk and fatality rates. We studied Coronavirus Disease 2019 (COVID-19)-antibody seroprevalence in a community sample drawn from Santa Clara County. On 3 and 4 April 2020, we tested 3328 county residents for immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies to SARS-CoV-2 using a rapid lateral-flow assay (Premier Biotech). Participants were recruited using advertisements that were targeted to reach county residents that matched the county population by gender, race/ethnicity and zip code of residence. We estimate weights to match our sample to the county by zip, age, sex and race/ethnicity. We report the weighted and unweighted prevalence of antibodies to SARS-CoV-2. We adjust for test-performance characteristics by combining data from 18 independent test-kit assessments: 14 for specificity and 4 for sensitivity. The raw prevalence of antibodies in our sample was 1.5% [exact binomial 95% confidence interval (CI) 1.1–2.0%]. Test-performance specificity in our data was 99.5% (95% CI 99.2–99.7%) and sensitivity was 82.8% (95% CI 76.0–88.4%). The unweighted prevalence adjusted for test-performance characteristics was 1.2% (95% CI 0.7–1.8%). After weighting for population demographics, the prevalence was 2.8% (95% CI 1.3–4.2%), using bootstrap to estimate confidence bounds. These prevalence point estimates imply that 53 000 [95% CI 26 000 to 82 000 using weighted prevalence; 23 000 (95% CI 14 000–35 000) using unweighted prevalence] people were infected in Santa Clara County by late March—many more than the ∼1200 confirmed cases at the time. The estimated prevalence of SARS-CoV-2 antibodies in Santa Clara County implies that COVID-19 was likely more widespread than indicated by the number of cases in late March, 2020. At the time, low-burden contexts such as Santa Clara County were far from herd-immunity thresholds.
登录
查看更多内容
影响因子：
82.9
作者：
Wu, Joseph T.;Leung, Kathy;Leung, Gabriel M.
通讯作者：
Leung, Gabriel M.
DOI：
10.1016/s0140-6736(20)32009-2
发表时间：
2020-10-24
期刊：
Lancet (London, England)
影响因子：
--
作者：
Anand S;Montez-Rath M;Han J;Bozeman J;Kerschmann R;Beyer P;Parsonnet J;Chertow GM
通讯作者：
Chertow GM
影响因子：
7.4
作者：
Shaver, Lance Garrett;Khawer, Ahmed;Wang, Peizhong Peter
通讯作者：
Wang, Peizhong Peter
DOI：
10.1016/s1473-3099(20)30243-7
发表时间：
2020-06-01
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Verity, Robert;Okell, Lucy C;Ferguson, Neil M
通讯作者：
Ferguson, Neil M
影响因子：
3.7
作者：
DEVILLE, JC;SARNDAL, CE;SAUTORY, O
通讯作者：
SAUTORY, O